Key result
Losartan combined with amlodipine reduced 24-hour ambulatory central systolic BP compared to losartan plus hydrochlorothiazide after 20 weeks.
Why the study?
To evaluate the non-inferiority of office mean systolic BP reduction and superiority of 24-hour ambulatory central BP reduction between losartan plus fixed-dose amlodipine versus losartan plus up-titrated hydrochlorothiazide.
Does losartan combined with amlodipine improve 24-hour ambulatory central BP reduction compared to losartan combined with hydrochlorothiazide in hypertensive patients?
RCT (n=231)
double-blind
randomized
Yes
Does losartan combined with amlodipine improve 24-hour ambulatory central BP reduction compared to losartan combined with hydrochlorothiazide in hypertensive patients?
The combination of losartan and amlodipine provides superior 24-hour ambulatory central blood pressure reduction compared to losartan and hydrochlorothiazide in hypertensive patients, despite similar office blood pressure reductions.
Answers are grounded in this paper and cite their sources.
Losartan-amlodipine warrants preference for central BP lowering in hypertension; extends RCT evidence on ARB add-on choices beyond office readings.
OBJECTIVE: The main objective of this study was to evaluate non-inferiority of office mean systolic blood pressure (BP) reduction efficacy and superiority of 24-hour ambulatory central BP reduction efficacy between losartan combined with fixed dose amlodipine (L/A group) and dose up-titrated hydrochlorothiazide (L/H group) according to office BP. METHODS: We conducted a prospective, randomized, double-blind multicenter trial in 231 patients with hypertensive (mean age = 59.2 ± 12.2 years). Patients received losartan 50 mg monotherapy for 4 weeks, followed by additional use of amlodipine 5 mg or hydrochlorothiazide 12.5 mg for 20 weeks after randomization. The patients who did not achieve the BP goal after 4 weeks' randomization received an increased dose of 100 mg/5 mg for the L/A group and 100 mg/25 mg for L/H group, respectively. The 24-hour ambulatory central BP was measured at baseline and after 20 weeks' treatment. RESULTS: Office mean systolic BP reduction of L/A group was not inferior to L/H group after 4 weeks' treatment (-17.6 ± 13.3 vs. -14.4 ± 12.6 mm Hg, P = 0.0863) and was not significantly different after 20 weeks' treatment. (-15.7 ± 14.0 vs. -14.7 ± 15.1 mm Hg, P = 0.6130) The 24-hour ambulatory central systolic BP was significantly more reduced in the L/A group compared with that in the L/H group after 20 weeks' treatment (-9.37 ± 10.67 vs. -6.28 ± 10.50 mm Hg, P = 0.0407). The 24-hour ambulatory central systolic BP at the completion of the study and its reduction magnitude were independently associated with reductions in aortic pulse wave velocity, pulse pressure, and wave reflection magnitude. CONCLUSION: Office systolic BP reduction with L/A was not inferior to L/H after 4 week's treatment. The combination of losartan and amlodipine was more favorable in 24-hour ambulatory central hemodynamics beyond BP-lowering efficacy than the combination of losartan and hydrochlorothiazide, regardless of office BP. CLINICAL TRIALS REGISTRATION: NCT02294539.
No takes yet. Share an insight, caveat, or question.
Cho et al. (2019) conducted an RCT in hypertension (n=231). Losartan combined with amlodipine vs. Losartan 50-100 mg plus hydrochlorothiazide 12.5-25 mg was evaluated on 24-hour ambulatory central systolic BP reduction after 20 weeks' treatment (p=0.0407). Losartan combined with amlodipine reduced 24-hour ambulatory central systolic BP compared to losartan plus hydrochlorothiazide after 20 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: